Managing Thin Corneas in CXL: Accelerated Protocols, Hypoosmolar Riboflavin and Trans-epithelial Approaches

For healthcare professionals. This content is intended for professional educational purposes and does not replace clinical judgement.

Thin corneas can be cross-linked, but only with protocols designed to protect the corneal endothelium, and the decision belongs at the specialist, protocol level rather than in routine practice. The traditional 400 µm minimum exists to shield the endothelium from ultraviolet-A (UV-A), so when the stroma is thinner, surgeons either thicken it, change how riboflavin is delivered, or tailor the UV-A dose to the individual cornea. Each approach trades some efficacy or predictability for safety.

This article reviews why thickness matters and compares the main strategies for thin-cornea cross-linking: hypoosmolar riboflavin, transepithelial techniques, accelerated and individualised fluence protocols, and contact lens-assisted CXL.

The dilemma is common. Thinning is part of how keratoconus progresses, so the corneas most likely to need stabilising are often the ones that fall below conventional thickness limits. A decade ago many of these eyes were simply turned away; today, several validated workarounds exist.

Why Corneal Thickness Matters in Cross-Linking

Cross-linking works by activating riboflavin in the stroma with UV-A, generating reactive oxygen species that stiffen the cornea. The same UV-A that drives the reaction can damage deeper structures if it reaches them at too high an intensity, which makes thickness a safety variable rather than a technical detail. The principle underpins every keratoconus treatment decision that involves CXL.

The endothelium has a known UV-A damage threshold, and the stroma saturated with riboflavin acts as the filter that keeps the delivered dose beneath it. Thickness, riboflavin concentration, and UV-A dose are therefore three levers that must stay in balance.

The 400-Micron Safety Threshold

The standard (Dresden) protocol requires at least 400 µm of stroma after epithelial removal. At that thickness, riboflavin saturation absorbs enough UV-A that the dose reaching the endothelium stays below its cytotoxic limit.

Below 400 µm, that safety margin shrinks. The threshold is not arbitrary; it reflects the depth at which the cross-linking effect and the UV-A dose are balanced against endothelial protection.

Risks of CXL in Thin Corneas

The principal risk of treating a thin cornea with a standard protocol is endothelial damage, which can lead to corneal oedema and decompensation. Because the endothelium does not regenerate, this is a serious and largely irreversible complication.

Other recognised risks of CXL, such as transient haze, delayed epithelial healing, and rare sterile infiltrates, also tend to weigh more heavily in compromised, very thin corneas, which reinforces the need for careful selection.

Thin corneas are common in advanced keratoconus, which are exactly the eyes most in need of stabilisation. Treating early, before the cornea thins or scars or develops acute corneal hydrops, remains the best strategy, but workable thin-cornea protocols matter for eyes that present late.

Strategies for Performing CXL in Thin Corneas

There are four broad strategies, and they are not mutually exclusive. One thickens the cornea (hypoosmolar riboflavin), one keeps the epithelium as a barrier (transepithelial), one adds a protective layer (contact lens-assisted), and one tailors the UV-A dose to the cornea (individualised fluence). All share a single goal: deliver useful cross-linking while keeping the endothelium safe.

Hypoosmolar Riboflavin for Corneal Swelling

How Hypoosmolar (Hypotonic) Riboflavin Works

Hypoosmolar riboflavin uses a lower-osmolarity solution to draw water into the stroma, swelling a thin cornea above the 400 µm threshold before UV-A is applied. Biotech’s FLAVIN HY, a hypotonic, dextran-free riboflavin, is formulated for this purpose.

Pre-Treatment Stromal Swelling to Reach Safe Thickness

In practice, the de-epithelialised cornea is treated with hypoosmolar riboflavin until pachymetry confirms it has reached at least 400 µm, after which standard irradiation can proceed. The main limitation is that the degree of swelling is unpredictable and can be uneven, so repeated intraoperative pachymetry is essential.

Accelerated cross-linking combined with hypoosmolar riboflavin has been reported with stabilisation maintained at two-year follow-up, although uneven swelling means the achieved depth of effect is less predictable than in a naturally thick stroma.

Dextran-Free Formulations

Conventional isotonic riboflavin often contains dextran, which tends to dehydrate and thin the stroma, the opposite of what a thin cornea needs. Dextran-free hypotonic formulations avoid that effect, which is why they are the logical choice when swelling is the aim.

Transepithelial (Epi-On) Cross-Linking

How the Epithelium-On Approach Differs

Transepithelial CXL leaves the epithelium intact. Because epithelial debridement itself removes roughly 50 µm of tissue, keeping the epithelium preserves thickness and avoids one source of thinning, while also improving comfort and lowering infection risk.

Enhancing Riboflavin Penetration

The epithelium is a barrier to riboflavin, so transepithelial protocols use penetration enhancers, such as benzalkonium chloride, EDTA, or trometamol, and sometimes iontophoresis, to help the molecule reach the stroma. Biotech’s FLAVIN TE is a dedicated transepithelial riboflavin developed for this approach.

Iontophoresis and oxygen-supplemented variants aim to push more riboflavin and oxygen into the stroma, narrowing the efficacy gap. For thin corneas specifically, the appeal is that avoiding debridement preserves the roughly 50 µm of epithelium and the stromal hydration that comes with it.

Pros and Cons vs Epithelium-Off CXL

The trade-off is efficacy. Transepithelial approaches generally achieve less cross-linking than standard epithelium-off treatment, with a shallower effect. They are attractive for comfort and for preserving thickness, but their weaker stiffening has to be weighed against the need to halt progression decisively.

Accelerated and Individualised Cross-Linking Protocols

Higher Irradiance, Shorter Treatment Time

Accelerated CXL raises UV-A irradiance and shortens exposure while keeping total energy constant, following the Bunsen–Roscoe reciprocity law. Because the reaction depends on oxygen, very high irradiance can outstrip the available oxygen, so pulsed delivery and supplemental oxygen are used to preserve the effect.

On its own, however, accelerating the treatment does not solve the thin-cornea problem. It must be combined with a thickness-management or dose-management strategy to keep the endothelium safe.

High-fluence pulsed protocols, which alternate UV-A on and off to let oxygen recover, are one way clinicians try to maintain stiffening at faster speeds. Even so, in a thin cornea the total dose still has to respect the endothelial limit.

Individualised (Sub400) Fluence

Rather than altering the cornea or the riboflavin, individualised protocols tailor the UV-A dose to the cornea’s measured thinnest point. The Sub400 protocol adjusts illumination time and irradiance to keep the depth of cross-linking a safe margin away from the endothelium.

Published data are encouraging. In ultrathin corneas down to around 214 µm of stroma, this approach achieved topographic stability in roughly 90% of eyes at one year, with no endothelial decompensation reported. It is, nonetheless, a specialised technique that depends on precise pachymetry and a validated nomogram.

Conceptually, it keeps the cross-linking front a fixed safe distance, on the order of 70 µm, from the endothelium by shortening illumination as the cornea gets thinner. That logic, treating each cornea to its own safe dose, is why individualised fluence is increasingly seen as the most rational approach to the very thin eye.

Contact Lens-Assisted CXL (CACXL)

CACXL places a riboflavin-soaked soft contact lens on the eye during treatment, adding an absorbing layer that, together with the riboflavin film, shields the endothelium. In effect, it increases the optical thickness the UV-A must pass through.

The trade-off is a meaningful reduction in cross-linking strength, with reports of roughly a third less stiffening effect. It remains a useful option in selected, very thin corneas where the other methods are unsuitable or insufficient.

Some surgeons reserve it for the thinnest corneas, or combine it with other measures, accepting the reduced stiffening as the price of a treatment that can be performed at all.

Choosing the Right Riboflavin Formulation

Isotonic vs Hypotonic vs Transepithelial Solutions

Formulation should follow the protocol, not the other way around. Isotonic riboflavin, such as Biotech’s FLAVIN, suits standard epithelium-off treatment in corneas of adequate thickness. Hypotonic riboflavin is chosen to swell thin corneas, and transepithelial formulations are designed to cross an intact epithelium.

Having a complete riboflavin product range on hand lets the surgeon match the solution to the chosen technique, which is the practical foundation of safe thin-cornea cross-linking.

In thin eyes, this usually means reaching first for a hypotonic, dextran-free solution, and reserving isotonic, dextran-containing riboflavin for corneas that are already thick enough.

Patient Selection and Outcomes in Thin Corneas

Thin-cornea cross-linking is for carefully selected, usually progressive, cases where the alternative is continued deterioration. The work-up centres on accurate pachymetry, tomography, and endothelial assessment, and the chosen protocol should be matched to the thinnest measured point.

Documented progression is the usual prerequisite, since the aim is to halt change rather than treat a stable cornea. Where safe stabilisation is not achievable, the conversation shifts toward visual rehabilitation and, ultimately, keratoplasty for the most advanced eyes.

Outcomes in experienced hands are good, with stabilisation rates approaching those of standard CXL when the protocol is appropriate to the cornea. Where the cornea is too compromised, or where ectasia is very advanced, other options, such as intrastromal ring segments or, in stable eyes, phakic lenses for keratoconus, may be considered alongside or instead of cross-linking.

The unifying message is that thin corneas are no longer an automatic exclusion, but they demand individualised, protocol-level decisions and meticulous intraoperative monitoring.

Frequently Asked Questions

Can cross-linking be done if the cornea is too thin?
Yes, in selected cases, using protocols designed to protect the endothelium. It is a specialist decision rather than a routine one.

What is the minimum corneal thickness for CXL?
The standard protocol needs at least 400 µm after epithelial removal. Specialised protocols can treat thinner corneas, in some reports down to around 214 µm of stroma.

What is hypoosmolar riboflavin used for?
It swells a thin cornea above 400 µm before UV-A, so that a standard dose can be applied more safely.

Is transepithelial CXL as effective as epithelium-off?
Generally no. It tends to achieve less cross-linking, although it preserves corneal thickness and patient comfort.

Is accelerated cross-linking safe for thin corneas?
Only when combined with a thickness- or dose-management strategy. On its own, it does not solve the endothelial-safety problem.

What happens if CXL is performed below 400 µm without precautions?
The UV-A dose reaching the endothelium may exceed its safe limit, risking endothelial damage and corneal decompensation.

Which thin-cornea protocol is best?
There is no single answer. The choice depends on the thinnest pachymetry, the available equipment, and surgeon experience; individualised fluence and hypoosmolar swelling are among the most established options.